Event Date/Time: Nov 04, 2009
End Date/Time: Nov 06, 2009
Early Registration Date:
Aug 07, 2009
Improving productsâ€™ clinical safety will increase the industryâ€™s fundamental value proposition to patients, healthcare providers, payors and regulators. The program will focus on pharmacovigilance program implementation and specific strategies and approaches to creating true value from a peri- and post-approval drug safety program. The approach of this conference is not to look at safety in the silos of early-phase safety or post-approval safety but to view safety holistically, across the lifecycle, especially at the transition from approval to broader use in the marketplace.
The special, three-day executive forum entitled â€œPost-Approval Drug Safety Strategies: Best Practices to Assess and Mitigate Risks throughout the Productâ€™s Life Cycleâ€ will tackle many of the pressing issues that executives are facing today.